Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antithrombotic theory
Biotech
CRISPR Tx, Sirius pen collab with a focus on thrombotic disease
CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx.
Ben Adams
May 20, 2025 3:59am
Bear research reveals potential drug target for blood clots
Apr 18, 2023 9:00am
Blackstone, Novartis found cardiovascular startup with $250M
Feb 27, 2019 9:37am
J&J buys into Bristol-Myers cardiovascular disease program
Apr 17, 2018 8:40am
